Sign in with Google
bearish
Eisai Co Ltd (4523 JP): Despite Sluggish Launch, Ambitious Long-Term Target Set for Leqembi
458 Views09 Mar 2024 01:30
SUMMARY
- Eisai Co Ltd (4523 JP) has come out with ambitious revenue target for Alzheimer’s disease drug Leqembi with new estimates for global eligible patient population and potential indication expansions.
- By FY27, Eisai expects Leqembi can generate revenue of ¥290B (~$2B) worldwide. Leqembi revenue can potentially ballooned to a whopping ¥1.6T (~$10.8B) by FY33, according to the company.
- Through January, Eisai could reach just 2,000 patients in the U.S. versus target of 10K patients by March. The sluggish progress of Leqembi makes Eisai’s target difficult to achieve.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Errors in Local Street's Projections for the KOSPI 200 Rebalancing
- Nikkei 225 Sep25 Rebal: One ADD, One DELETE Still Probable, Kokusai a Question but $3bn+ a Side
- KOSPI200 Index Rebalance Preview: 7 Changes a Side for June
- CSI300 Index Rebalance Preview: 8 Changes a Side in June; US$4.5bn Trade
- [Quiddity Index] MV Jr-Gold Miners Jun25 Leaderboard: Flow Expectations
Top Unpaywalled Insights
More »- India-UK Free Trade Agreement: A New Era for India's Textile Industry
- The Rise of Quant Investing in Crypto w/ Truvius CEO Connor Farley | The New Barbarians #007
- New Research: Unlocking Quantitative Alpha in Cryptocurrency Markets
- The Evolution of Portfolio Management: Bridging Traditional Models and Machine Learning
- Fractured Markets: Economic Consequences of the 2025 Tariffs
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Eisai Co Ltd (4523 JP): Mixed H1FY25 Performance; Guidance Reaffirmed; Leqembi Struggle Continues21 Nov 2024
- Eisai Co Ltd (4523 JP): New Competition Is Coming for Alzheimer’s Disease Drug; No Immediate Threat03 Jul 2024
- Eisai Co Ltd (4523 JP): Leqembi Is Gathering Momentum; Imminent Competition May Spoil the Party16 May 2024
- Eisai Co Ltd (4523 JP): Why Performance Reversal Is Not Expected in Near-Term03 Jan 2024
- Eisai Co (4523 JP): Better-Than-Expected Q1FY24 Result; Reaffirmed FY24 Guidance05 Aug 2023
x